Northstar Response Data Encouraging, But High Bar In Oncology Remains

Research evidence excerpt

Northstar Response Data Encouraging, But High Bar In Oncology Remains

USA | Life Science Tools & Diagnostics

BillionToOne EquityJuneResearch29, 2026

FLASH NOTENorthstar Response Data Encouraging, But High

RATING HOLDBar In Oncology Remains

PRICE $120.40^

Today, BLLN announced publication of a peer-reviewed study showcasing

the clinical utility of Northstar Response as an early response/progression PRICE TARGET | % TO PT $94.00 | -22%

biomarker during IO, 62 days before imaging. This data, alongside recent 52W HIGH-LOW $138.70 - $61.96

channel checks highlighting BLLN's platform technological superiority, provide FLOAT (%) | ADV MM (USD) 42.1% | 94.53

upbeat signals, although we remain balanced in our outlook as much of the MARKET CAP $6.4B

recent move (to 9x EV/'27 sales) reflects future oncology momentum. Reiterate TICKER BLLN ^Prior trading day's closing price unless otherwise

Hold. noted.

Northstar Response data. BLLN announced the publication of a peer-reviewed study (142 patients,

12 solid tumor types) highlighting Northstar Response as a stronger predictor of survival than

standard-of-care (SoC) imaging in patients with advanced solid tumors receiving immunotherapy

(IO). Specifically, the study highlighted a detection of cancer progression at a median of 62 days

before radiographic evidence, with molecular progression PFS HR of 5.3. Additionally, the data

illustrated that a combined approach with molecular and imaging assessments drove higher hazard

ratios (13.8 at landmark, 19.7 with continued longitudinal monitoring), suggesting potential clinical

utility in incorporating both diagnostic modalities.

AlphaSense channel check (former Clinical Genomics Specialist at Natera)... 1) NIPT. The KOL